Interim update on human studies and extension of IP portfolio

Interim update on human studies and extension of IP portfolio

Manchester, UK - 31 January 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, provides interim data on the third and final phase of its human studies and an update on one of its patents....

31st January, 2019 Read More

Business review

Business review

CEO, Prof Cath O'Neill provides a review on 2018 and outlook for the key aspects of 2019. ...

14th December, 2018 Read More

Commencement of final phase of human studies

Commencement of final phase of human studies

Manchester, UK - 20 November 2018 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces the commencement of the third and final phases of its human study and provides a summary of key scientific a...

20th November, 2018 Read More

SkinBiotix® technology generates positive data in first two elements of its human study

SkinBiotix® technology generates positive data in first two elements of its human study

Manchester, UK - 7 November 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces positive data from the first two elements of its human study which focus on skin irritancy and moisturisation potential....

7th November, 2018 Read More

Full Year Results

Full Year Results

Manchester, UK - 25 October 2018 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company") a life sciences company focused on skin health, has announced its full year results for the year to 30 June 2018....

25th October, 2018 Read More

CEO Presentation

CEO Presentation

CEO, Prof. Cath O'Neill presenting at the AJ Bell Investor Evening https://www.sharesmagazine.co.uk/video/dr-catherine-oneill-ceo-skinbiotherapeutics-sbtx-2...

17th October, 2018 Read More
investors logo